Angela DeMichele, MD, examines the important findings in breast cancer research as revealed at ASCO 2017, with a focus on the OLYMPIAD trial of the PARP1 inhibitor olaparib in metastatic breast cancer patients with a germline BRCA mutation, and an overview of the CDK 4/6 inhibitors palbociclib, ribociclib and abemaciclib. Despite a lack of overall survival data for olaparib, Dr. DeMichele notes the drug’s 3 month progression-free survival (PFS) benefit vs. standard-of-care chemotherapy in the population studied and its likely approval in breast cancer in the near future. Of the three cdk 4/6 inhibitors, Dr. DeMichele observes, all are equally good at prolonging PFS in combination with endocrine therapy in the metastatic setting—though resistance to these agents is universal.
Related Links:
Published
November 17, 2017
Created by
BROADCASTMED